The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zykov V.P.

Russian Medical Academy Continuing Professional Education

Komarova I.B.

Russian Medical Academy Continuing Professional Education

Diagnosis, pathogenesis and treatment of attention deficiency syndrome

Authors:

Zykov V.P., Komarova I.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(6): 22‑29

DOI: 10.17116/jnevro202312306122

Views: 9373

Downloaded: 203

Download PDF (RU)
Contact the author
Table of contents

DIAGNOSIS, PATHOGENESIS AND TREATMENT OF ATTENTION DEFICIENCY SYNDROME
DIAGNOSIS, PATHOGENESIS AND TREATMENT OF ATTENTION DEFICIENCY SYNDROME

To cite this article:

Zykov VP, Komarova IB. Diagnosis, pathogenesis and treatment of attention deficiency syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(6):22‑29. (In Russ.)
https://doi.org/10.17116/jnevro202312306122

Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Anxiety diso­rders as como­rbid conditions in neuropsychiatric diseases in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7):56-64
The blood content of 25-OH vita­min D and biogenic amines in resi­dents of Arkhangelsk city. Russian Journal of Preventive Medi­cine. 2024;(11):108-114

Attention deficit hyperactivity disorder is the dominant form of cognitive and behavioral dysfunctions in childhood, the disease has a chronic course and manifests in adolescents and adults in 50—80% of cases. An adequate diagnosis is the testing of parents and teachers using the Conners questionnaire in two stages, the second is mandatory after 6 months to confirm the persistence of symptoms over time. The pathogenesis is based on violations of mediation of dopamine and norepinephrine in the fronto-striate-thalamic system, responsible for the function of constant attention, caused by molecular genetic mechanisms. Atomoxetine (Cognitera) in combination with pedagogical and psychological methods of correction seems to be an adequate drug for many months of use, taking into account international and Russian experience of use.

Keywords:

attention deficit hyperactivity disorder
dopamine
norepinephrine
atomoxetine

Authors:

Zykov V.P.

Russian Medical Academy Continuing Professional Education

Komarova I.B.

Russian Medical Academy Continuing Professional Education

Received:

29.03.2023

Accepted:

01.06.2023

List of references:

  1. Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387(10024):1240-1250. https://doi.org/10.1016/S0140-6736(15)00238-X
  2. Rowland AS, Skipper BJ, Umbach DM, et al. The prevalence of ADHD in a population-based sample. J Atten Disord. 2015 Sep;19(9):741-754.  https://doi.org/10.1177/1087054713513799
  3. Sacco R, Camilleri N, Eberhardt J, et al. A systematic review and meta-analysis on the prevalence of mental disorders among children and adolescents in Europe. Eur Child Adolesc Psychiatry. 2022 Dec 30;1-18.  https://doi.org/10.1007/s00787-022-02131-2
  4. Winters KC, Botzet AM, Fahnhorst T, et al. Impulsivity and its Relationship to Risky Sexual Behaviors and Drug Abuse. J Child Adolesc Subst Abuse. 2009 Jan 1;18(1):43-56.  https://doi.org/10.1080/15470650802541095
  5. Molina BS, Pelham WE Jr. Attention-deficit/hyperactivity disorder and risk of substance use disorder: developmental considerations, potential pathways, and opportunities for research. Annu Rev Clin Psychol. 2014;10:607-639.  https://doi.org/10.1146/annurev-clinpsy-032813-153722
  6. Childress AC, Berry SA. Pharmacotherapy of attention-deficit hyperactivity disorder in adolescents. Drugs. 2012;72(3):309-325.  https://doi.org/10.2165/11599580-000000000-00000
  7. Thapar A, Cooper M, Eyre O, Langley K. What have we learnt about the causes of ADHD? J Child Psychol Psychiatry. 2013;54(1):3-16.  https://doi.org/10.1111/j.1469-7610.2012.02611.x
  8. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/ hyperactivity disorder. Biol Psychiatry. 2005;57(11):1313-1323. https://doi.org/10.1016/j.biopsych.2004.11.024
  9. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997 Jan;121(1):65-94.  https://doi.org/10.1037/0033-2909.121.1.65
  10. LaHoste GJ, Swanson JM, Wigal SB, et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol Psychiatry. 1996 May;1(2):121-124. 
  11. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009;126(1):51-90.  https://doi.org/10.1007/s00439-009-0694-x
  12. Arcos-Burgos M, Castellanos FX, Lopera F, et al. Attention-deficit/hyperactivity disorder (ADHD): feasibility of linkage analysis in a genetic isolate using extended and multigenerational pedigrees. Clin Genet. 2002 May;61(5):335-343.  https://doi.org/10.1034/j.1399-0004.2002.610503.x
  13. Gao Q, Liu L, Qian Q, Wang Y. Advances in molecular genetic studies of attention deficit hyperactivity disorder in China. Shanghai Arch Psychiatry. 2014 Aug;26(4):194-206.  https://doi.org/10.3969/j.issn.1002-0829.2014.04.003
  14. Christakis DA, Zimmerman FJ, DiGiuseppe DL, et al. Early television exposure and subsequent attentional problems in children. Pediatrics. 2004;113:708-713.  https://doi.org/10.1542/peds.113.4.708
  15. Kessi M, Duan H, Xiong J, et al. Attention-deficit/hyperactive disorder updates. Front Mol Neurosci. 2022 Sep 21;15:925049. eCollection 2022. https://doi.org/10.3389/fnmol.2022.925049
  16. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009;126(1):51-90.  https://doi.org/10.3389/fnmol.2022.925049
  17. González S, Moreno-Delgado D, Moreno E, et al. Circadian-related heteromerization of adrenergic and dopamine D4 receptors modulates melatonin synthesis and release in the pineal gland. PloS Biol. 2012;10(6):e1001347. https://doi.org/10.1371/journal.pbio.1001347
  18. Rubinstein M, Cepeda C, Hurst RS, et al. Dopamine D4 receptor-deficient mice display cortical hyperexcitability. J Neurosci. 2001;21(11):3756-3763. https://doi.org/10.1523/JNEUROSCI.21-11-03756.2001
  19. Bonaventura J, Quiroz C, Cai NS, et al. Key role of the dopamine D4 receptor in the modulation of corticostriatal glutamatergic neurotransmission. Sci Adv. 2017;3(1)e:1601-1631. https://doi.org/10.1126/sciadv.1601631
  20. Mill J, Curran S, Richards S, et al. Polymorphisms in the dopamine D5 receptor (DRD5) gene and ADHD. Am J Med Genet B Neuropsychiatr Genet. 2004 Feb 15;125B(1):38-42.  https://doi.org/10.1002/ajmg.b.20127
  21. van Kempen J, Brandt C, Distler C, et al. Dopamine influences attentional rate modulation in Macaque posterior parietal cortex. Sci Rep. 2022 Apr 28;12(1):6914. https://doi.org/10.1038/s41598-022-10634-w
  22. Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci. 1997 Nov 1;17(21):8528-8535. https://doi.org/10.1523/JNEUROSCI.17-21-08528.1997
  23. Meng HR, Suenaga T, Edamura M, et al. Functional MHCI deficiency induces ADHD-like symptoms with increased dopamine D1 receptor expression. Brain Behav Immun. 2021 Oct;97:22-31.  https://doi.org/10.1016/j.bbi.2021.05.015
  24. Yokokura M, Takebasashi K, Takao A, et al. In vivo imaging of dopamine D1 receptor and activated microglia in attention-deficit/hyperactivity disorder: a positron emission tomography study. Mol Psychiatry. 2021 Sep;26(9):4958-4967. https://doi.org/10.1038/s41380-020-0784-7
  25. Tegelbeckers J, Kanowski M, Krauel K, et al. Orbitofrontal Signaling of Future Reward is Associated with Hyperactivity in Attention-Deficit/Hyperactivity Disorder. J Neurosci. 2018 Jul 25;38(30):6779-6786. https://doi.org/10.1523/JNEUROSCI.0411-18.2018
  26. Shalev N, Vangkilde S, Neville MJ, et al. Dissociable Catecholaminergic Modulation of Visual Attention: Differential Effects of Catechol-O-Methyltransferase and Dopamine Beta-Hydroxylase Genes on Visual Attention. Neuroscience. 2019 Aug 1;412:175-189.  https://doi.org/10.1016/j.neuroscience.2019.05.068
  27. Fernandez F, Byrne MK, Batterham M, et al. Associations between Omega-3 index, dopaminergic genetic variants and aggressive and metacognitive traits: a study in adult male prisoners. Nutrients. 2022 Mar 25;14(7):1379. https://doi.org/10.3390/nu14071379
  28. Pineau G, Villemonteix T, Slama H, et al. Dopamine transporter genotype modulates brain activity during a working memory task in children with ADHD. Res. Dev. Disabil. 2019;92:103430. https://doi.org/10.1016/j.ridd.2019.103430
  29. Diamond A. Consequences of variations in genes that affect dopamine in prefrontal cortex. Cereb Cortex. 2007 Sep;17 Suppl 1(Suppl 1):i161-70.  https://doi.org/10.1093/cercor/bhm082
  30. Borodovitsyna O, Flamini M, Chandler D. Noradrenergic Modulation of Cognition in Health and Disease. Neural Plast. 2017;2017:6031478. https://doi.org/10.1155/2017/6031478
  31. Wang B, Wang Y, Zhou R, et al. Possible association of the alpha-2A adrenergic receptor gene (ADRA2A) with symptoms of attention-deficit/hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet. 2006;141B(2):130-134.  https://doi.org/10.1002/ajmg.b.30258
  32. Park L, Nigg JT, Waldman ID, et al. Association and linkage of alpha-2A adrenergic receptor gene polymorphisms with childhood ADHD. Mol Psychiatry. 2005;10(6):572-580.  https://doi.org/10.1038/sj.mp.4001605
  33. Bundesen C. A theory of visual attention. Psychol Rev. 1990;97:523-547. 
  34. Shalev N, Vangkilde S, Neville MJ, et al. Dissociable Catecholaminergic Modulation of Visual Attention: Differential Effects of Catechol-O-Methyltransferase and Dopamine Beta-Hydroxylase Genes on Visual Attention. Neuroscience. 2019 Aug 1;412:175-189.  https://doi.org/10.1016/j.neuroscience.2019.05.068
  35. Puig MV, Gulledge AT. Serotonin and prefrontal cortex function: neurons, networks, and circuits. Mol Neurobiol. 2011 Dec;44(3):449-464.  https://doi.org/10.1007/s12035-011-8214-0
  36. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry. 1998 Aug 1;44(3):151-162.  https://doi.org/10.1016/s0006-3223(98)00139-5
  37. Zuo L, Saba L, Lin X, et al. Significant association between rare IPO11-HTR1A variants and attention deficit hyperactivity disorder in Caucasians. Am J Med Genet B Neuropsychiatr Genet. 2015 Oct;168(7):544-556.  https://doi.org/10.1002/ajmg.b.32329
  38. Park YH, Lee KK, Kwon HJ, et al. Association between HTR1A gene polymorphisms and attention deficit hyperactivity disorder in Korean children. Genet Test Mol Biomarkers. 2013;17(3):178-182.  https://doi.org/10.1089/gtmb.2012.0214
  39. Tegelbeckers J, Kanowski M, Krauel K, et al. Orbitofrontal Signaling of Future Reward is Associated with Hyperactivity in Attention-Deficit/Hyperactivity Disorder. J Neurosci. 2018 Jul 25;38(30):6779-6786. https://doi.org/10.1523/JNEUROSCI.0411-18.2018
  40. Miguel PM, Deniz BF, Deckmann I, et al. Prefrontal cortex dysfunction in hypoxic-ischaemic encephalopathy contributes to executive function impairments in rats: potential contribution for attention-deficit/hyperactivity disorder. World J Biol Psychiatry. 2018;19(7):547-560.  https://doi.org/10.1080/15622975.2016.1273551
  41. Thapar A, Rice F, Hay D, et al. Prenatal smoking might not cause attention-deficity/hyperactivity disorder: Evidence from a novel design. Biological Psychiatry. 2009;66:722-727. 
  42. Bhutta AT, Cleves MA, Casey PH, et al. Cognitive and behavioral outcomes of school-aged children who were born preterm: A meta-analysis. Journal of the American Medical Association. 2002;288:728-737. 
  43. Wolraich ML, Hagan JF Jr, Allan C, et al. Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. Pediatrics. 2019 Oct;144(4):e20192528. https://doi.org/10.1542/peds.2019-2528
  44. Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry. 1998;59 Suppl 7:24-30. 
  45. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (Revision). Washington, 2000. 943 p. 
  46. Zykov VP, Begasheva OI. Diagnostic methods and main approaches to the treatment of attention deficit hyperactivity disorder. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2011;111(9 Pt 2):32-36. (In Russ.).
  47. Luria A.R. Higher cortical functions of a person and their disturbances in local brain lesions. M.: Academic project. 2000. 512 p. (In Russ.).
  48. Pingault JB, Viding E, Galéra C, et al. Genetic and Environmental Influences on the Developmental Course of Attention-Deficit/Hyperactivity Disorder Symptoms From Childhood to Adolescence. JAMA Psychiatry. 2015 Jul;72(7):651-658.  https://doi.org/10.1001/jamapsychiatry.2015.0469
  49. Menkes J. Child Neurology. 2007; 34(3):1156.
  50. Newkiktien C. Children’s behavioral neurology. Translated from English. Vol. 2. M.: Terevinf, 2010, p. 336. (In Russ.).
  51. Zykov VP, Kashirina ES, Naugolnykh YuV. Methods of objective monitoring of the effectiveness of therapy in children with tics. Neurological Bulletin. Journal them. V.M. Bekhtereva. 2016;2:35-41. (In Russ.).
  52. Weinberg WA, Brumback RA. Primary disorder of vigilance: a novel explanation of inattentiveness, daydreaming, boredom, restlessness, and sleepiness. J. Pediatr. 1990;116(5):720-725.  https://doi.org/10.1016/s0022-3476(05)82654-x
  53. Picchietti MA, Picchietti DL. Advances in pediatric restless legs syndrome: Iron, genetics, diagnosis and treatment. Sleep Med. 2010 Aug;11(7):643-651.  https://doi.org/10.1016/j.sleep.2009.11.014
  54. Tumashenko AF. The effectiveness of Pantocalcin in the treatment of attention deficit hyperactivity disorder in children and adolescents. Consilium medium. Pediatrics. 2006;2:56-58. (In Russ.).
  55. Sukhotina NK, Konovalova VV, Kryzhanovskaya IL, Kupriyanova TA. Efficacy of pantogam in the treatment of hyperkinetic disorders in children. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2010;110(12):24-28. (In Russ.).
  56. Musatova NM. Pantocalcin in the treatment of attention deficit hyperactivity disorder. Difficult patient. 2006;6(4):2-3. (In Russ.).
  57. Martenyi F, Zavadenko NN, Jarkova NB, et al. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: a 6-week, randomized, placebo-controlled, double-blind trial In Russia. Eur Child Adolesc Psychiatry. 2010 Jan;19(1):57-66.  https://doi.org/10.1007/s00787-009-0042-7
  58. Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):511-518.  https://doi.org/10.1097/CHI.0b013e31819c55b2
  59. Gamal F, El Agami O, Salamah A. Coenzyme Q10 in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Randomized Controlled Trial. CNS Neurol Disord Drug Targets. 2022;21(8):717-723.  https://doi.org/10.2174/1871527320666211124093345
  60. Wietecha L, Williams D, Shaywitz S, et al. Atomoxetine improved attention in children and adolescents with attention-deficit/hyperactivity disorder and dyslexia in a 16 week, acute, randomized, double-blind trial. J Child Adolesc Psychopharmacol. 2013 Nov;23(9):605-613.  https://doi.org/10.1089/cap.2013.0054
  61. Biederman J, Heiligenstein JH, Faries DE, et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Dec;110(6):e75.  https://doi.org/10.1542/peds.110.6.e75
  62. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018 Sep;5(9):727-738.  https://doi.org/10.1016/S2215-0366(18)30269-4
  63. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711.  https://doi.org/10.1016/S0893-133X(02)00346-9
  64. Kowalczyk OS, Cubillo AI, Smith A, et al. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents. Eur Neuropsychopharmacol. 2019;29(10):1102-1116. https://doi.org/10.1016/j.euroneuro.2019.07.139

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.